natgillin/translations-raw huggingface dataset:
The immunogenicity of the A/Vietnam/1203/2004 strain vaccine has been evaluated in three clinical studies in adults aged 18 – 59 years (N=961) and in two clinical studies in subjects aged 60 years and older (N=391) following a 0, 21 day schedule.
Imunogenost cepilnega seva A/Vietnam/1203/2004 je bila ocenjena v treh kliničnih študijah pri odraslih, starih od 18 do 59 let (N=961) in v dveh kliničnih študijah pri starostnikih, starih 60 let in več (N=391), in sicer po shemi cepljenja 0. in 21. dan.
The immunogenicity of the vaccine containing 7.5 µg non-adjuvanted HA derived from strain A/Vietnam/1203/2004 has been evaluated in two clinical studies in adults aged 18 – 59 years (N = 312) and in older subjects aged 60 years and older (N = 272) following a 0, 21 day schedule.
Imunogenost cepiva, ki vsebuje 7,5 µg HA brez adjuvansa, izdelanega s sevom A/Vietnam/1203/2004, je bila ocenjena v dveh kliničnih študijah pri odraslih, starih od 18 do 59 let (n=312), in pri starejših osebah, starih 60 let ali več (n=272), in sicer po shemi cepljenja na prvi in 21. dan.
The immunogenicity of Vaxelis in children over 15 months of age has not been studied in clinical trials.
Imunogenost cepiva Vaxelis pri otrocih, starejših od 15 mescev, ni bila raziskana v kliničnih preskušanjih.
The immunoglobulin IgG subclasses are:
Podskupine imunoglobulinov IgG so:
The immunological response may be diminished if the patient is undergoing immunosuppressant treatment.
Če se bolnik zdravi z imunosupresivnimi zdravili, je odziv imunskega sistema lahko manjši.
The impact of gender on the pharmacokinetics of Sivextro was evaluated in healthy males and females in clinical studies and in a population pharmacokinetics analysis.
Vpliv spola na farmakokinetiko zdravila Sivextro so ocenili pri zdravih moških in ženskah v kliničnih študijah in populacijskih farmakokinetičnih analizah.
The impact of hepatic impairment on the pharmacokinetics of guanfacine in paediatric patients (children and adolescents 6-17 years old) was not assessed.
Vpliva okvare jeter na farmakokinetiko gvanfacina pri pediatričnih bolnikih (otroci in mladostniki, stari 6-17 let) niso ocenjevali.
The impact of long- term treatment with Humira on the development of autoimmune diseases is unknown.
Vpliv dolgoročnega zdravljenja z zdravilom Humira na nastanek avtoimunskih bolezni ni znan.
The impact of long- term treatment with Trudexa on the development of autoimmune diseases is unknown.
Vpliv dolgoročnega zdravljenja s Trudexo na nastanek avtoimunskih bolezni ni znan.
The impact of long-term treatment with Cimzia on the development of autoimmune diseases is unknown.
Vpliv dolgotrajnega zdravljenja z zdravilom Cimzia na nastanek avtoimunih bolezni ni znan.
The impact of macrolides and azole antifungal agents on stiripentol metabolism, that are known to be inhibitors of CYP3A4 and substrates of the same enzyme, is not known.
Vpliv makrolidov in azolnih učinkovin proti mikozam, ki so znani zaviralci CYP3A4 in substrati tega encima, na presnovo stiripentola ni znan.
The impact of moderately impaired liver function (Child-Pugh class B) on the pharmacokinetics of bosentan and its primary metabolite Ro 48-5033 was investigated in a study including 5 patients with pulmonary hypertension associated with portal hypertension and Child-Pugh class B hepatic impairment, and 3 patients with pulmonary arterial hypertension from other causes and normal liver function.
Vpliva zmerno okvarjenega delovanja ledvic (razred B po klasifikaciji Child-Pugh) na farmakokinetiko bosentana in njegov primarni presnovek Ro 48-5033 so raziskali v študiji, v katero je bilo vključenih 5 bolnikov s pljučno hipertenzijo, povezano s portalno hipertenzijo in okvarjenim delovanjem jeter razreda B po klasifikaciji Child-Pugh, in 3 bolniki s pljučno arterijsko hipertenzijo zaradi drugih razlogov in normalnim delovanjem jeter.
The impact of nausea and vomiting on patients’ daily lives was assessed using the Functional Living Index–Emesis (FLIE).
Vpliv navzee in bruhanja na vsakodnevno življenje bolnikov so ocenili z lestvico Functional Living Index–Emesis (FLIE).
The impact of oclacitinib administration on vaccination with modified live vaccines, canine parvovirus (CPV), canine distemper virus (CDV) and canine parainfluenza (CPI) and inactivated rabies vaccine (RV), on 16 week old vaccine naïve puppies has been studied.
Pri predhodno necepljenih mladičih, starih 16 tednov, so preučili vpliv oklacitiniba na cepljenje z modificiranimi živimi cepivi, pasji m parvovirusom (CPV), virusom pasje kuge (CDV) in virusom pasje parainfluence (CPI) ter inaktiviranim cepivom proti steklini (RV).
The impact of oclacitinib administration on vaccination with modified live vaccines, canine parvovirus (CPV), canine distemper virus (CDV) and canine parainfluenza (CPI) and inactivated rabies vaccine (RV), on 16 week old vaccine naïve puppies has been studied.
Pri predhodno necepljenih mladičih, starih 16 tednov, so preučili vpliv oklacitiniba na cepljenje z modificiranimi živimi cepivi, pasjim parvovirusom (CPV), virusom pasje kuge (CDV) in virusom pasje parainfluence (CPI) ter inaktiviranim cepivom proti steklini (RV).
The impact of predominant telaprevir-resistant variants at baseline is likely greatest in patients with a poor interferon response, such as prior null responders.
Pomen prevladujočih na telaprevir odpornih variant pred začetkom zdravljenja je verjetno največji pri bolnikih s slabim odzivom na interferon, kot so na primer bolniki, ki se niso odzvali na zdravljenje.
The impact of prior dasabuvir, ombitasvir, or paritaprevir treatment experience on the efficacy of other NS5A inhibitors, NS3/4A protease inhibitors, or NS5B inhibitors has not been studied.
Vpliv predhodnega zdravljenja z dasabuvirjem, ombitasvirjem ali paritaprevirjem na učinkovitost drugih zaviralcev NS5A, zaviralcev proteaz NS3/4A ali zaviralcev NS5B ni raziskan.
The impact of renal impairment on the pharmacokinetics of guanfacine in paediatric patients (children and adolescents 6-17 years old) was not assessed.
Vpliva okvare ledvic na farmakokinetiko gvanfacina pri pediatričnih bolnikih (otroci in mladostniki, stari 6-17 let) niso ocenjevali.
The impact of the vaccine in terms of public health and control of the human infection cannot be estimated from available data.
Vpliva cepiva na zdravje ljudi in obvladovanje okuženosti ljudi iz razpoložljivih podatkov ni mogoče oceniti.
The impact of the vaccine on total number of episodes of otitis media regardless of etiology was a 6 % (95 % CI: -4, 16) reduction.
Cepivo je zmanjšalo celotno število izbruhov vnetja srednjega ušesa ne glede na etiologijo za 6 % (95-odstotni interval zaupanja: -4, 16).
The impact of treatment with Xiapex on subsequent surgery, if needed, is not known.
Vpliv zdravljenja z zdravilom Xiapex na naknadno operacijo, če je potrebna, ni znan.
The implant contains 16 mg of afamelanotide.
Implantat vsebuje 16 mg afamelanotida.
The implant is an opaque, off-white membrane, seeded with chondrocytes, supplied in 18 ml of colourless solution in a dish.
Vsadek je neprozorna, belkasta membrana, nacepljena s hondrociti, na voljo v 18-mililitrski brezbarvni raztopini v posodici.
The implant is inserted directly under the skin folds on your waist or abdomen in an area known as the supra-iliac crest.
Implantat se vstavi neposredno pod kožno gubo na pasu ali trebuhu, tj. območju, ki se imenuje suprailiakalna krista.
The implant is made of a material that dissolves over several months while gradually releasing the dexamethasone.
Vsadek je narejen iz snovi, ki se raztaplja več mesecev, pri čemer se postopoma sprošča deksametazon.
The implant may be administered to bitches from the age of four months.
Implantat lahko uporabimo od starosti štirih mesecev naprej.
The implant should be administered subcutaneously between the shoulder blades of the dog or ferret.
Implantat dajte psu ali belemu dihurju subkutano med lopaticama.
The implant should be administered subcutaneously between the shoulder blades of the dog.
Implantat dajajte psu subkutano med lopaticama.
The implantation should be followed by an appropriate rehabilitation schedule for approximately one year, as recommended by the physician (see section 4.4).
Implantaciji mora slediti ustrezen rehabilitacijski načrt za približno eno leto po priporočilih zdravnika (glejte poglavje 4.4).
The import, possession, sale, supply and/or use of this veterinary medicinal product is or may be prohibited in certain a Member States on the whole or part of their territory, see package leaflet for further information.
Uvoz, prodaja, oskrba in/ali uporaba tega zdravila je ali je lahko prepovedana v nekaterih državah članicah na njihovem celotnem ozemlju ali delu ozemlja; za nadaljnje informacije glej navodilo za uporabo.
The import, sale, supply and/or use of CaniLeish is or may be prohibited in certain Member States on the whole or part of their territory pursuant to national animal health policy.
Uvoz, prodaja, dobava in/ali uporaba CaniLeish je ali je lahko prepovedana v določenih državah članicah v celoti ali delno na celotnem ozemlju ali delu njihovega ozemlja v skladu z nacionalnim programom zdravstvenega varstva živali.
The import, sale, supply and/or use of Nobivac Bb for cats is or may be prohibited in certain Member States on the whole or part of their territory pursuant to national animal health policy.
Uvoz, prodaja, oskrba in/ali uporaba zdravila Nobivac Bb za mačke je ali je lahko prepovedana v nekaterih državah članicah na njihovem celotnem ozemlju ali delu ozemlja v skladu z nacionalnim programom zdravstvenega varstva živali.
The import, sale, supply and/or use of Rhiniseng is or may be prohibited in certain Member States on the whole or part of their territory pursuant to national animal health policy.
Uvoz, prodaja, oskrba in/ali uporaba zdravila Rhiniseng je ali je lahko prepovedana v nekaterih državah članicah na njihovem celotnem ozemlju ali delu ozemlja v skladu z nacionalnim programom zdravstvenega varstva živali.
The import, sale, supply and/or use of this veterinary medicinal product is or may be prohibited in certain Member States on the whole or part of their territory pursuant to national animal health policy.
Uvoz, prodaja, oskrba in/ali uporaba tega zdravila za uporabo v veterinarski medicini je ali je lahko prepovedana v nekaterih državah članicah na njihovem celotnem ozemlju ali delu ozemlja v skladu z nacionalnim programom zdravstvenega varstva živali.
The import, sale, supply and/or use of this veterinary medicinal product is or may be prohibited in certain Member States on the whole or part of their territory pursuant to national animal health policy.
Uvoz, prodaja, oskrba in/ali uporaba tega zdravila za uporabo v veterinarski medicini je ali je lahko prepovedana v nekaterih državah članicah na njihovem celotnem ozemlju ali delu ozemlja, v skladu z nacionalnim programom zdravstvenega varstva živali.
The import, sale, supply and/or use of VIRBAGEN OMEGA is or may be prohibited in certain Member States on the whole or part of their territory pursuant to national animal health policy.
Uvoz, prodaja, oskrba in/ali uporaba VIRBAGEN OMEGA je prepovedana v nekaterih državah članicah na njihovem celotnem ozemlju ali delu ozemlja v skladu z nacionalnim programom zdravstvenega varstva živali.
The importance of apparent differences in tissue distribution between Myocet and conventional doxorubicin has not been elucidated with respect to long-term antitumour efficacy.
Pomena očitnih razlik v porazdelitvi zdravila Myocet in običajnega doksorubicina v tkivih v smislu dolgoročne učinkovitosti proti tumorjem niso razložili.
The importance of avoiding inadvertent switching between tacrolimus containing products and the risk of under and overdosing if monitoring is inadequate.
Pomembnost preprečitve nenamernih prehodov med zdravili, ki vsebuje takrolimus, in tveganje premajhnega ali prevelikega odmerjanja, če spremljanje ni ustrezno.
The importance of avoiding switching between other tacrolimus containing products except under the advice and supervision of physicians.
Pomembno je preprečiti menjavanje z drugimi zdravili, ki vsebujejo takrolimus, razen po nasvetu in pod nadzorom zdravnika.
The importance of carrying the detachable wallet-sized Patient Alert Card at all times to show it at all medical visits to healthcare professionals other than the prescriber (e.g. emergency healthcare professionals).
Pomembnost, da imajo bolniki ves čas pri sebi opozorilno kartico, ki jo morajo pokazati pri vsakem obisku zdravnika (npr. nujna zdravniška pomoč), razen ob obisku zdravnika, ki je zdravilo predpisal.
The importance of carrying the Patient Alert Card at all times and to show it at all medical visits to healthcare professionals other than the prescriber (e.g. emergency healthcare professionals).
Opozorilo, naj imajo opozorilno kartico za bolnike ves čas pri sebi in jo pokažejo ob vseh obiskih pri drugih zdravnikih (npr. na urgenci).
The importance of concurrent dexamethasone administration should be emphasised at the initiation of each cycle of DepoCyte treatment.
Pomembnost sočasne uporabe deksametazona morate poudariti na začetku vsakega kroga zdravljenja z zdravilom DepoCyte.
The importance of explaining the use of the new graduated syringe and correct injection technique to patients and/or caregivers
pomembnost razlaganja uporabe nove odmerne injekcijske brizge in pravilne tehnike injiciranja bolnikom in/ali negovalcem, pomembnost zagotavlja izobraževalnega gradiva za bolnike in/ali negovalce.
The importance of measuring creatinine clearance
pomembnost merjenja očistka kreatinina;
The importance of monitoring for clinical signs and symptoms of hypersensitivity and that patients should alert their doctor if they develop such symptoms during or after receiving Ruconest.
pomen spremljanja kliničnih znakov in simptomov preobčutljivosti in da morajo bolniki opozoriti svojega zdravnika, če razvijejo take simptome med prejemanjem ali po prejemu zdravila Ruconest;
The importance of not attempting to self-treat any symptoms without consulting their Healthcare professional
Pomembnost, da bolnik ne poskuša zdraviti simptomov sam, brez predhodnega posveta z zdravstvenim delavcem.
The importance of not attempting to self-treat any symptoms without consulting their healthcare professional first
Opozorilo, naj bolniki ne poskušajo sami zdraviti katerih koli simptomov, ne da bi se posvetovali z zdravnikom
The importance of not attempting to self-treat any symptoms without consulting their Healthcare professional first.
Pomembnost, da bolnik ne začne zdraviti simptomov brez predhodnega posveta z zdravnikom.
The importance of reading the “IONSYS Instructions for Use and Disposal” including the troubleshooting guide and ensuring that the patient understands what to do in the event of a device failure/malfunction.
Kako pomembno je prebrati »navodila za uporabo in odstranjevanje zdravila Ionsys«, vključno z vodnikom za odpravljanje težav, in zagotoviti, da bolnik razume, kaj storiti ob okvari ali nepravilnem delovanju pripomočka.
The importance of regular monitoring of renal function during Atripla therapy
Pomembnost rednega spremljanja ledvičnega delovanja med zdravljenjem z zdravilom Atripla
The importance of the healthcare professional ensuring that the patient understands how to operate the IONSYS system and that only he/she can press the dosing button during use.
Kako pomembno je, da zdravstveni delavec bolnika pouči o delovanju sistema Ionsys in da sme med uporabo samo on pritiskati gumb za odmerjanje.
The important patient information leaflets for the Medtronic MiniMed implantable insulin pump system.
Pomembnimi navodili za uporabo implantabilnega sistema insulinske črpalke Medtronic MiniMed.
The improved glycaemic control is associated with reductions in both fasting and post- prandial glucose.
Boljšo urejenost glikemije spremlja znižanje glukoze na tešče in postprandialne glukoze.
The improved glycaemic control is associated with reductions in both fasting and post- prandial glucose.
Izboljšana urejenost glikemije je povezana z zmanjšanjem koncentracije glukoze tako na tešče kot po jedi.
The improvement appeared rapidly (within weeks) after starting Fampyra.
Izboljšanje se je pojavilo hitro (v nekaj tednih) po začetku jemanja zdravila Fampyra.
The improvement in the proportion of patients who achieved SVR was consistent across all subgroups in the randomisation strata (baseline platelet counts (< 50,000 vs. > 50,000), viral load (< 800,000 IU/ml vs. ≥ 800,000 IU/ml) and genotype (2/3 vs.
Pri deležu bolnikov, ki so dosegli SVR je bilo izboljšanje konsistentno v vseh podskupinah randomizirane skupine bolnikov (število trombocitov v izhodišču (< 50.000 v primerjavi z > 50.000), virusna obremenitev (< 800.000 IU/ml v primerjavi z ≥ 800.000 IU/ml) in genotip (2/3 v primerjavi z 1/4/6)).
The improvement in walk distance was apparent from 8 weeks of treatment.
Izboljšanje prehojene razdalje je bilo opazno po 8 tednih zdravljenja.
The improvements in ppFEV1 observed in patients treated with lumacaftor/ivacaftor in Trial 1 or Trial 2 were sustained in Trial 3 (Figure 1).
Izboljšanja ppFEV1, ugotovljena pri bolnikih, zdravljenih z lumakaftorjem/ivakaftorjem) v preskušanju 1 ali preskušanju 2, so se vzdrževala v preskušanju 3 (slika 1).
The improvements were generally maintained in subjects who were re-randomized to Otezla at Week 32 through Week 52 (Table 5).
Izboljšanja so na splošno trajala pri preiskovancih, ki so jih po 32 tednih ponovno randomizirali na zdravilo Otezla, do 52. tedna (preglednica 5).
The in vitro activity of anidulafungin against Candida species is not uniform.
Dejavnost anidulafungina proti vrsti Candida in vitro ni enotna.
The in vitro antiviral activity of elvitegravir when combined with antiretroviral drugs from the nucleos(t)ide reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI), integrase strand transfer inhibitor, fusion inhibitor, or CCR5 co-receptor antagonist classes showed no antagonism.
Protivirusna aktivnost elvitegravirja in vitro v kombinaciji z drugimi protiretrovirusnimi zdravili iz razredov nukleozidnih zaviralcev reverzne transkriptaze (NRTI), nenukleozidnih zaviralcev reverzne transkriptaze (NNRTI), zaviralcev proteaze (PI), zaviralcev prenosa zapisa integraze, zaviralcev fuzije ali zaviralcev soreceptorjev CCR5 ni kazala antagonizma.
The in vitro antiviral activity of lopinavir against laboratory and clinical HIV strains was evaluated in acutely infected lymphoblastic cell lines and peripheral blood lymphocytes, respectively.
Protivirusno delovanje lopinavirja proti laboratorijskim in kliničnim sevom virusa HIV so in vitro ocenili pri akutno okuženih limfoblastnih celičnih linijah (laboratorijski sevi) in limfocitih periferne krvi (klinični sevi).
The in vitro antiviral activity of telbivudine was assessed in the HBV-expressing human hepatoma cell line 2.2.15. The concentration of telbivudine that effectively inhibited 50% of viral synthesis (EC50) was approximately 0.2 M.
Protivirusno delovanje telbivudina so in vitro preskušali na celični liniji humanega hepatoma 2.2.15, ki je izražala viruse hepatitisa B. Koncentracija telbivudina, ki je učinkovito zavrla 50% virusne sinteze (EC50), je bila približno 0,2 mol/l.
The in vitro antiviral EC50 of lopinavir is approximately 10-fold lower than that of ritonavir.
Protivirusna EC50 lopinavirja in vitro je približno 10-krat manjša kot ritonavirja.
The in vitro plasma protein binding of ambrisentan was, on average, 98.8% and independent of concentration over the range of 0.2 – 20 microgram/ml.
Vezava ambrisentana na plazemske proteine je bila in vitro v povprečju 98,8-odstotna in v razponu od 0,2 do 20 mikrogramov/ml neodvisna od koncentracije.
The in vitro protein binding of olaparib at plasma concentrations achieved following dosing at 400 mg twice daily is ~82%.
Ob koncentraciji v plazmi, ki je dosežena ob uporabi 400 mg dvakrat na dan, je vezava olapariba na beljakovine in vitro ~82 %.
The in vivo relevance is unknown.
Pomen tega in vivo ni znan.
The in vivo relevance of these interactions is not clear.
Pomen interakcij in vivo ni jasen.
The in-use stability of KIOVIG after dilution with a 5% glucose solution to a final concentration of 50 mg/ml (5%) immunoglobulin has been demonstrated for 21 days at 2°C to 8°C as well as 28°C to 30°C; however, these studies did not include the microbial contamination and safety aspect.
Dokazali so, da je po redčenju s 5 % raztopino glukoze do končne koncentracije 50 mg immunoglobulina/ml (5 %) zdravilo KIOVIG med uporabo stabilno 21 dni pri temperaturi od 2°C do 8°C, pa tudi pri temperaturi od 28°C do 30°C, vendar v teh študijah niso upoštevali mikrobne kontaminacije in varnostnega vidika.
The in-use stability of Privigen after dilution with a 5% glucose solution to a final concentration of 50 mg/ml (5%) has been demonstrated for 10 days at 30°C; however, the microbial contamination aspect was not studied.
Dokazana je bila 10-dnevna stabilnost zdravila Privigen po razredčitvi s 5- odstotno raztopino glukoze do končne koncentracije 50 mg/ml (5 %) pri 30 °C; vendar vidika mikrobne kontaminacije niso preučili.
The inactive ingredients of Betaferon include small amounts of mannitol, a naturally occurring sugar and human albumin, a protein.
Zdravilo Betaferon vsebuje kot pomožni snovi majhne količine manitola (naravni sladkor) in humanega albumina (beljakovina).
The inactive ingredients of Betaferon include small amounts of mannitol, a naturally occurring sugar, and human albumin, a protein.
Zdravilo Betaferon vsebuje kot pomožni snovi majhne količine manitola (naravni sladkor) in humanega albumina (beljakovina).
The inactive ocriplasmin/α2-antiplasmin complex is cleared from the circulation with a half-life (t1/2) of several hours.
Inaktivirani kompleks okriplazmina/α2-antiplazmina se izloči iz obtoka z razpolovnim časom (t1/2) nekaj ur.
The incidence and frequency of moderate or greater flushing in patients treated with Pelzont for the duration of the study decreased.
Pri bolnikih, zdravljenih z zdravilom Pelzont, sta se pojavnost in pogostnost zmernega ali izrazitejšega zardevanja v času študije zmanjšali.
The incidence and nature of symptoms after the first and second vaccination were similar to that observed in the adult and older population using Celvapan.
Pojavnost in narava simptomov po prvem in drugem cepljenju sta bili podobni kot pri odraslih in starostnikih, ki so prejeli cepivo Celvapan.
The incidence and severity of adverse events is dose-dependent.
Pogostnost in stopnja izraženosti neželenih učinkov je odvisna od odmerka.
The incidence is about 5- 9 %.
Pogostnost teh pojavov je približno 5 do 9 %.
The incidence observed was also higher in patients less than 75 years old, treated with roflumilast when compared to those treated with placebo (3.1% vs 2.0%).
Večjo pojavnost so opazili tudi pri bolnikih, mlajših od 75 let, ki so se zdravili z roflumilastom, v primerjavi z bolniki, ki so prejemali placebo (3,1 % v primerjavi z 2,0 %).
The incidence of a FEV1 reduction > 15% from baseline after Rapiscan administration was assessed in three randomised, controlled clinical studies.
Incidenca zmanjšanja FEV1 > 15% od izhodišča po dajanju zdravila Rapiscan je bila ocenjena v treh randomiziranih, nadziranih kliničnih študijah.
The incidence of a-GVHD grades I-II was 46.4% (13/28), while the incidence of grade III-IV was 3.6% (1/28).
Pojavnost aGVHD stopnje I-II je bila 46,4 % (13/28), medtem ko je bila pojavnost stopnje III- IV 3,6 % (1/28).
The incidence of abnormal, but not clinically significant, findings on breast palpation and mammography decreased in the ospemifene 60 mg population during the 1-year study (Trial 3) from 1.6% to 0.6% and from 11.8% to 8.1% respectively.
Incidenca nenormalnih, a klinično nepomembnih izsledkov pri palpaciji dojk in na mamografiji se je v 1-letni študiji pri populaciji z ospemifenom 60 mg zmanjšala (preskušanje 3) z 1,6% do 0,6% oz. z 11,8% do 8,1%.
The incidence of acute graft versus host disease (a-GVHD) data was collected in allogeneic patients (n=28).
Podatki o pogostosti akutne reakcije presadka proti gostitelju (acute graft-versus-host disease – a-GVHD) so bili zbrani pri alogenskih bolnikih.